These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25561337)

  • 1. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
    Viljoen J; Azie N; Schmitt-Hoffmann AH; Ghannoum M
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1671-9. PubMed ID: 25561337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
    Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
    Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
    Krause DS; Simjee AE; van Rensburg C; Viljoen J; Walsh TJ; Goldstein BP; Wible M; Henkel T
    Clin Infect Dis; 2004 Sep; 39(6):770-5. PubMed ID: 15472806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis.
    Wilcox CM; Darouiche RO; Laine L; Moskovitz BL; Mallegol I; Wu J
    J Infect Dis; 1997 Jul; 176(1):227-32. PubMed ID: 9207371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
    de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
    Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.
    Skiest DJ; Vazquez JA; Anstead GM; Graybill JR; Reynes J; Ward D; Hare R; Boparai N; Isaacs R
    Clin Infect Dis; 2007 Feb; 44(4):607-14. PubMed ID: 17243069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole for treatment of rare invasive fungal diseases.
    Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Perfect JR; Oren I; Schmitt-Hoffmann AH; Giladi M; Marty FM; Rahav G
    Mycoses; 2018 Aug; 61(8):518-533. PubMed ID: 29611246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
    de Wet NT; Bester AJ; Viljoen JJ; Filho F; Suleiman JM; Ticona E; Llanos EA; Fisco C; Lau W; Buell D
    Aliment Pharmacol Ther; 2005 Apr; 21(7):899-907. PubMed ID: 15801925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis.
    Brand SR; Degenhardt TP; Person K; Sobel JD; Nyirjesy P; Schotzinger RJ; Tavakkol A
    Am J Obstet Gynecol; 2018 Jun; 218(6):624.e1-624.e9. PubMed ID: 29534874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
    Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
    Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
    Livermore J; Hope W
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole shortens the QTc interval.
    Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
    Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.
    Majithiya J; Sharp A; Parmar A; Denning DW; Warn PA
    J Antimicrob Chemother; 2009 Jan; 63(1):161-6. PubMed ID: 19008255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis.
    Li T; Zhu Y; Fan S; Liu X; Xu H; Liang Y
    Med Mycol; 2015 Jun; 53(5):455-61. PubMed ID: 25877666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
    Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
    Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
    Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group.
    Barbaro G; Barbarini G; Di Lorenzo G
    Chest; 1996 Dec; 110(6):1507-14. PubMed ID: 8989069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.
    Vazquez JA; Skiest DJ; Tissot-Dupont H; Lennox JL; Boparai N; Isaacs R
    HIV Clin Trials; 2007; 8(2):86-97. PubMed ID: 17507324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.